Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 01:00 ET | Source: Addex Therapeutics

Addex Convenes Annual General Meeting 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
March 24, 2022 02:00 ET | Source: Addex Therapeutics

Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences

Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
March 10, 2022 01:10 ET | Source: Addex Therapeutics

Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase 2b/3 dipraglurant study in dyskinesia...
March 07, 2022 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022

Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
February 24, 2022 01:00 ET | Source: Addex Therapeutics

Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums

Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
February 03, 2022 01:00 ET | Source: Addex Therapeutics

Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
January 11, 2022 01:00 ET | Source: Addex Therapeutics

Addex to Present at the Swiss Equities Baader Virtual Conference

Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
January 06, 2022 01:00 ET | Source: Addex Therapeutics

Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
December 17, 2021 01:00 ET | Source: Addex Therapeutics

Addex Raises $10.0 Million in Equity Financing

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
December 15, 2021 01:00 ET | Source: Addex Therapeutics

Addex Provides Year End Pipeline Development Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...